|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 October 2007, Vol. 110, No. 8, pp. 3083.
CORRESPONDENCE Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem-cell transplantationTo the editor:Armand and colleagues suggest a possible link between pretransplantation ferritin levels and outcome after myeloablative hematopoietic stem cell transplantation (HSCT), especially in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).1 In general, treatment-related mortality after HSCT is mostly caused by either graft-versus-host disease (GVHD) or infection-related complications. It is of note that the negative impact of iron overload on transplantation-related mortality was not attributable to a higher incidence of acute GVHD. Therefore, it would be interesting to know what the causes of death were in this group of patients. One suggestion is that these patients experienced fatal infections more frequently. The nature (bacterial versus fungal) could have also implications on prophylaxis and surveillance regimens after transplantation. Nevertheless, our concern is that the transfusion load as mirrored by ferritin level is rather a reflection of the disease stage. High ferritin levels and a long history of transfusion support are closely correlated with a longer interval from diagnosis to HSCT. At the same time, the duration and depth of disease-associated neutropenia might have been longer, leading to a higher frequency of opportunistic infections. Therefore, we would like to ask the authors to incorporate duration of neutropenia (absolute neutrophil count [ANC] < 1.8 x 109/L [< 1800/µL]) as well as time from diagnosis to HSCT into the proportional hazard model in order to confirm the ferritin level as an independent risk factor in this setting. In addition, our conclusion from the presented data might be different from that of Armand et al proposing appropriate iron chelating therapy in these patients. We think that the current decision model2 of when to perform a HSCT in an individual patient must be rather extended, taking also into account the duration and frequency of transfusion support, which has also a negative impact of disease-free survival regardless of International Prognostic Scoring System (IPSS) score.3 This could disembogue into earlier intervention strategies proposing transplantation in a patient (eg, with INT-1–risk MDS in case of severe red cell transfusion dependency before clinical manifestation of iron load or transformation to higher IPSS stage). Authorship Conflict-of-interest disclosure: U.P. has received financial support from Novartis for a conference lecture. All other authors declare no competing financial interests. Correspondence: Dr Uwe Platzbecker, Universitaetsklinikum Carl Gustav, Carus, Fetscherstr. 74, 01307 Dresden, Germany; email: uwe.platzbecker{at}uniklinikum-dresden.de.
References
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
